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relative efficacies of three possible therapeutic strategies (e.g.,
Coronary artery bypass graft surgery [CABG], percutaneous cor-
onary intervention [PCI], and medical therapy [MT]) for patients
with multivessel coronary artery disease (CAD), stable angina, and
preserved ventricular function.
At one-year follow-up, 79% in the PCI group and 46% in the
MT group were free of angina. Medical therapy, however, was
associated with a lower incidence of short-term events (e.g.,
myocardial infarction or death) and a reduced need for additional
revascularization, compared with PCI (1).
It appears that patients allocated to the different arms were not
blinded to the treatment prescribed, which means that both PCI
and medically treated patients were aware of the fact that they did
or did not undergo mechanical intervention. Thus, the superiority
of PCI compared to MT as an antiangina therapy may at least
partially be due to the placebo effect. Similar placebo effect may
also affect the results of the Second Randomized Intervention
Treatment of Angina (RITA-2) study (2) for the same reason.
The placebo effect can be powerful indeed, as was proven in the
case of percutaneous transmyocardial revascularization (PTMR):
after a few unblinded, randomized trials of PTMR, patients with
refractory angina demonstrated significant relief of angina. A
well-conducted blinded randomized study, however, showed
PTMR does not result in a greater reduction in angina, as
compared with MT (3).
If the placebo effect is responsible, even in part, for angina relief
by PCI, then PCI is an even less appealing option for patients with
multivessel CAD, stable angina, and preserved ventricular func-
tion, considering the lower incidence of short-term events associ-
ated with MT, demonstrated by the MASS-II study.
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REPLY
We thank Dr. Rott for his comments regarding our article (1). In
the MASS-II study, 59% of patients treated with coronary artery
bypass graft surgery (CABG) and 52% treated percutaneously were
free of angina at one year, figures significantly better than the 36%
of patients without symptoms in the medically treated group (with
no difference between surgery and stenting). As pointed out by Dr.
Rott, a placebo effect related to the invasive nature of the former
modalities cannot be ruled out as a possible component to justify
the symptomatic improvement among these patients. However, we
should emphasize that the difference in the symptomatic status of
the study groups was paralleled by a highly significant reduction in
the rate of objective ischemia among the groups, which was greater
for the surgical and percutaneous groups (36% and 18%, respec-
tively) than for medically treated patients (5%). Therefore, we trust
that most (if not all) of the symptom relief observed among
patients treated with myocardial revascularization might have been
related to actual ischemia reduction.
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